Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.52 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.52 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2432179 | 0.90 | CYP4F2 (0.56) | CYP4F2CYP4A11TLR7KMT2ALMNA | |
| SCHEMBL2623696 | 0.86 | TLR7 (0.47) | CYP4F2CYP4A11TLR7KMT2A | |
| SCHEMBL491276 | 0.84 | CYP4F2 (0.59) | CYP4F2CYP4A11KMT2ALMNASMN1; SMN2 | |
| SCHEMBL25118388 | 0.83 | CYP4F2 (0.55) | CYP4F2CYP4A11CYP4Z1ALOX5 | |
| SCHEMBL4459432 | 0.83 | TLR7 (0.53) | CYP4F2CYP4A11TLR7 | |
| SCHEMBL8984891 | 0.83 | CYP4F2 (0.58) | CYP4F2CYP4A11KMT2ALMNASMN1; SMN2 | |
| SCHEMBL2632416 | 0.83 | CYP4F2 (0.58) | CYP4F2CYP4A11KMT2ALMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6986396 | 0.82 | CYP4F2 (0.54) | CYP4F2CYP4A11TLR7KMT2ATNF | |
| Hydrochloric Acid SCHEMBL27590314 | 0.82 | CYP4F2 (0.54) | CYP4F2CYP4A11TLR7CYP4Z1 | |
| SCHEMBL27407292 | 0.82 | CYP4F2 (0.54) | CYP4F2CYP4A11DPP4CYP4Z1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544835-B2 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-05-27 | — | — | US | disclosed |
| EP-1380562-A1 | CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF | Eisai Co., Ltd. (JP) | 2004-01-14 | — | — | EP | disclosed |
| CN-1156443-A | Benzocycloalkene compound, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-08-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102634-A1 | Carboxylic acid derivative and salt thereof | GPR119, IRS1, SLC5A1 | CYP4F2 792/4885CYP4A11 188/4885TLR7 600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.